Holocene Advisors’s Aclaris Therapeutics ACRS Stock Holding History

Holocene Advisors’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,485,056	Closed	-$15.4M	–	707
2023 Q2	$15.4M	Hold	1,485,056	–	–	0.07%	227
2023 Q1	$12M	Sell	1,485,056 -178,619	-11%	-$2.27M	0.06%	228
2022 Q4	$26.2M	Sell	1,663,675 -397,243	-19%	-$6.39M	0.16%	158
2022 Q3	$32.4M	Hold	2,060,918	–	–	0.21%	142
2022 Q2	$28.8M	Hold	2,060,918	–	–	0.17%	160
2022 Q1	$35.5M	Buy	2,060,918 +2,300	+0.1%	+$31.4K	0.19%	148
2021 Q4	$29.9M	Buy	2,058,618 +103,013	+5%	+$1.56M	0.16%	167
2021 Q3	$35.2M	Buy	1,955,605 +557,233	+40%	+$8.93M	0.19%	153
2021 Q2	$24.6M	Buy	1,398,372 +872,509	+166%	+$19.8M	0.14%	178
2021 Q1	$13.3M	Buy	+525,863	New	+$10.3M	0.08%	204

Other funds holding ACRS

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Holocene Advisors's ACRS Position: Q3 2023 in Review

Holocene Advisors sold out of Aclaris Therapeutics (ACRS) in Q3 2023, closing a stake of 1,485,056 shares — an estimated $15.4M sold.

Holocene Advisors first reported a position in ACRS in Q1 2021 and held it in 10 quarters. The position peaked at $35.5M in Q1 2022. 137 funds tracked by Wall St. Rank hold ACRS as of Q3 2023.

Holocene Advisors reported no remaining Aclaris Therapeutics position as of Q3 2023 after selling out during the quarter.
Holocene Advisors sold 1,485,056 Aclaris Therapeutics shares in Q3 2023, an estimated $15.4M.
Holocene Advisors first reported a position in Aclaris Therapeutics in Q1 2021 and held it in 10 quarters.
Holocene Advisors's Aclaris Therapeutics position peaked at $35.5M in Q1 2022.
137 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2023.

Based on Holocene Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.